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Abstract
Quality cancer care requires identifying and addressing the psychosocial needs of cancer patients. 
Oncology social workers have long been on the forefront of this endeavor. Although there has 
been longstanding interest in screening cancer patients for distress, it has recently been included as 
a quality of care metric in institutions accredited by the American College of Surgeons. 
Implementing routine screening for distress in oncology settings requires thoughtful planning, 
including assessing various screening instruments and considering a host of variables within each 
practice setting. Oncology social workers are best positioned to provide leadership in 
operationalizing this mandate and to lead their team in the choice of a distress measure for 
compliance with the screening guideline. This article highlights the most popular distress 
screening measures used in oncology and their psychometric properties.
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Oncology social workers (OSWs) have provided psychosocial support to cancer patients 
since the 1940s, having been “the first, alongside nurses, to attend to the psychological and 
social problems of cancer patients and their families” (Abrams, 1974; Holland, 2002, p. 
214). Today, OSWs remain the primary professionals in the health care setting who provide 
psychosocial services to cancer patients and their significant others (Association of 
Oncology Social Work, 2001) and, as such, are essential members of the oncology team 
(Fobair, 2007; Hermann & Carter, 1994; Holland, 2002; Rohan & Bausch, 2009; Stearns, 
Lauria, Hermann, & Fogelberg, 1993). In recent years, the Institute of Medicine (IOM; 
2008) recognized that quality cancer care requires identifying and addressing the 
psychosocial needs of cancer patients. To that end, the American College of Surgeons 
(ACoS) Commission on Cancer (CoC; 2012) required psychological distress screening for 
every cancer patient treated in ACoS-accredited facilities.
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This requirement heightens the importance of OSWs’ proficiency in understanding and 
facilitating the administration of distress screening instruments. The current health care 
environment demands high caseloads and leaves limited time for an OSW to assess the 
myriad distress screening instruments, which is necessary if OSWs are to play an active role 
in determining which of these instruments to use and how to administer them. This article 
summarizes three commonly used instruments and discusses the strengths and weaknesses 
of each. The standards encourage institutions to use standardized, validated measures with 
established clinical cutoff scores; however, the standards also state that facilities are free to 
use any measure of their choice and determine their own cutoff score to identify distressed 
patients (CoC, 2012). The purpose of this article is to assist OSWs in the evaluation and 
selection of distress screening tools, and thus meet the CoC standards concerning distress 
screening.
ASSESSMENT OF DISTRESS SCREENING INSTRUMENTS
Evaluators of screening measures will most likely select instruments based on a balance of 
scientific evidence and the feasibility of implementing the instrument within a particular 
setting and with a particular patient population.
Scientific Criteria
Instruments are graded on their psychometric properties, that is, their ability to accurately 
and consistently measure the concept(s) of interest, in this case, distress. The National 
Comprehensive Cancer Network (NCCN; 2012), a nonprofit alliance of 21 leading 
comprehensive cancer centers in the United States, defines distress in cancer patients as a 
“multifactorial, unpleasant emotional experience of a psychological (cognitive, behavioral, 
emotional), social, and/or spiritual nature that may interfere with the ability to cope 
effectively with cancer, its physical symptoms, and its treatment.” Psychometric properties 
of measurement instruments are calculated mathematically and reported as reliability, 
validity, sensitivity, and specificity. In the sections to follow the psychometric properties of 
select measures are described plainly and specifically in relation to distress screening.
Reliability—Reliability refers to an instrument’s ability to measure a concept over time, 
across individuals, and in different contexts. An important component of reliability is an 
instrument’s internal consistency. If a measure is internally consistent, it means that 
different questions that measure the same concept are answered similarly by respondents. In 
other words, if three questions on a scale measure anxiety, but in different ways, a 
respondent should theoretically answer them similarly. Internal consistency is often 
measured and reported as Cronbach’s alpha (α), a score that ranges from .0 to 1.0 
(Cronbach, 1951). The closer to 1.0 the Cronbach’s alpha score is, the more reliable the 
measure. An internal consistency of .8 or higher is generally considered acceptable 
(Vodermaier, Linden, & Siu, 2009). If planning to use an instrument repeatedly over time, or 
as a pre- and postintervention measure, it is important to select one for which published 
reports indicate that the measure reliably captures change over time. Finally, the ability of 
respondents to comprehend screening questions in terms of their reading level or cultural 
relevance also reflects upon the instrument’s reliability. Instruments that have been 
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translated into languages other than English require their own psychometric evaluations and 
reporting of reliability statistics.
Validity—There are many ways to assess validity (e.g., face validity, content validity, 
concurrent validity, criterion validity, construct validity), but the overall definition is the 
degree to which an instrument actually measures what it intends to measure. For example, 
an instrument assessing symptoms of anxiety would not be a valid measure of depression 
because symptoms of anxiety are not necessarily indicative of depression. Similarly, if a 
measure of depression did not assess one’s level of interest or pleasure in daily activities—a 
critical aspect of depression as defined by the Diagnostic and Statistical Manual (American 
Psychiatric Association, 2000)—then that proposed measure would not be considered a 
valid or useful measure of depression. Validity statistics indicate how well a measure 
captures the multiple and varied aspects of the concept it seeks to measure (construct 
validity). They also indicate the extent to which a measure correlates with other instruments 
assessing similar outcomes (concurrent validity). For example, given that depression is 
likely associated with poor quality of life, a valid measure of depression would likely be 
significantly correlated with a separate quality-of-life measure. As new instruments are 
developed and tested in the oncology setting, they are compared with other instruments (or 
techniques, such as a clinical interview) that have already been shown to be valid in 
measuring distress.
Sensitivity and specificity—Related to reliability and validity are sensitivity and 
specificity. Stated simply, sensitivity refers to the degree to which an instrument detects 
distress when it actually exists. Specificity refers to the degree to which an instrument 
accurately measures no distress when it does not exist. If a distress test is highly sensitive 
but not specific, it will detect distress in too many people, that is, those experiencing distress 
and also some who are not (false-positives). If a test lacks sensitivity but is highly specific, it 
will detect those with the highest levels of distress but will fail to detect distress in some 
others who are experiencing it (false-negative). Sensitivity and specificity scores are 
reported as decimals ranging from .0 to 1.0, with higher scores indicating more sensitivity or 
specificity (e.g., a sensitivity score of 1.0 indicates that an instrument, at a particular cutoff 
score, will identify 100% of distressed persons). In practical terms, a cutoff score used to 
indicate clinically-significant distress is calculated by determining the best balance of 
sensitivity and specificity statistics (Hoffman, Zevon, D’Arrigo, & Cecchini, 2004; Jacobsen 
et al., 2005; Vodermaier et al., 2009).
Implementation Criteria
Implementation criteria speak to the practicality of using a measure in a clinical setting. 
These criteria encompass access to the measure, the ease of use of a measure, and the 
resources needed for scoring the measure. Although, undoubtedly, there are facility-specific 
issues (e.g., staffing availability) and population-specific issues (e.g., languages spoken by 
the patient population) that affect the practicality of implementing routine distress screening 
for oncology patients, there are important issues that must be considered across contexts. 
The analysis that follows first focuses on the scientific merits and the feasibility for 
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implementation of the distress measures most commonly applied in oncology and then 
summarizes the strengths and weaknesses of using each measure in a clinical setting.
INSTRUMENTS MOST COMMONLY USED IN ONCOLOGY SETTINGS
The instruments most commonly used in oncology settings are the Hospital Anxiety and 
Depression Scale (HADS), the Brief Symptom Inventory–18 (BSI-18), and the Distress 
Thermometer (DT). Each of these measures has an internal consistency (Cronbach’s alpha 
score) of .8 or higher (Vodermaier et al., 2009). These instruments are characterized as 
ultrashort, short, and long or standard, based on number of items (questions) contained in or 
time needed to administer the instrument (Mitchell, Kaar, Coggan, & Herdman, 2008; 
Vodermaier et al., 2009).
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) is a short, 14-item self-report 
instrument that measures two domains (anxiety and depression) in physically ill (as opposed 
to psychiatric) patients, and takes 2 to 5 minutes to complete (Snaith, 2003). Each domain 
has seven items that measure symptomology within the last week, and severity scores range 
from 0 to 3 for each item. HADS scores are summed and range from 0 to 21 for each 
domain. A cutoff score of ≥15 for either anxiety or depression indicates distress that requires 
psychosocial intervention (Jacobsen et al., 2005). The HADS is available in a variety of 
languages (English, Spanish, Dutch, French, German, Swedish, Italian, Chinese, Japanese, 
Urdu, Hebrew, and Arabic) (Snaith, 2003) for a fee from ACER Psychology (Snaith & 
Zigmond, 2012).
Strengths and limitations—The HADS is generally reported to possess sound 
psychometric properties (Carlson & Bultz, 2003; Sellick & Edwardson, 2007; Vodermaier & 
Millman, 2011), with a majority of studies reporting sensitivity ranging from .70 to 1.00 and 
corresponding specificity ranging from .70 to .90 (Vodermaier et al., 2009). As such, the 
HADS has often been the measure against which other distress measures have been 
evaluated in cancer care (Akizuki et al., 2003; Baken & Woolley, 2011; Holland, 2002; Roth 
et al., 1998; Vodermaier & Millman, 2011). Additionally,, although, as noted, Jacobsen et 
al. (2005) recommend a cutoff scale of ≥15, instrument authors offer a more precise 
algorithm: 8 to 10 represent mild cases, 11 to 15 represent moderate cases, and ≥16 
represent severe cases of anxiety or depression, which may assist OSWs in prioritizing 
follow-up with patients (Snaith & Zigmond, 2012). Another strength of the HADS is the 
variety of languages in which it is available, making it suitable for use with persons from a 
broad range of linguistic and cultural backgrounds. Importantly, HADS responses can be 
scored easily and used immediately in a clinical setting (Mitchell et al., 2008).
An important consideration and potential limitation of the HADS is the cost of obtaining the 
instrument for use in routine screening of all cancer patients.
Brief Symptom Inventory–18
The Brief Symptom Inventory–18 (BSI-18) is a short, 18-item self-report instrument that 
measures a patient’s symptoms of somatization, depression, and anxiety over the past week. 
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The instrument takes approximately 2 minutes to administer (Derogatis, 2012). The BSI-18 
provides a global severity index, indicative of an overall distress level. It can be 
administered via pencil and paper or with the PAD (Patient Assessment Device), a hand-
held electronic device. The resources required for scoring vary greatly. Scoring can be 
accomplished locally (by hand, optical scan, or computer via the PAD) or remotely by 
faxing completed instruments to the publisher, who will process them within 2 hours of 
receipt and return them by fax. Zabora et al. offer an additive scoring mechanism and 
suggest using cutoff scores of ≥10 for men and ≥13 for women, or a global score of ≥63 for 
identifying cancer patients in need of psychosocial intervention (Bevans et al., 2011; Zabora 
et al., 2001). The BSI-18, including associated manuals and services, is available in English 
and Spanish for purchase from Pearson Assessments (Derogatis, 2012).
Strengths and limitations—The BSI-18 is consistently reported to have sound 
psychometric properties (Bevans et al., 2011; Carlson & Bultz, 2003; Vodermaier et al., 
2009; Zabora, Diaz, & Loscalzo, 2003; Zabora & Knight, 2001), with cancer patient studies 
reporting sensitivity and specificity of .91 to .97 and .85 to .93, respectively (Zabora et al., 
2001; Recklitis et al., 2006). The BSI-18 provides information on a patient’s experiences 
across three domains (somatization, depression, and anxiety) in addition to a global score. 
Such detailed information is useful in the clinical setting, because it can help focus the 
formal psychosocial assessment. The BSI-18 has the capability to produce a progress report 
that displays a patient’s scores on each of the domains for the past five administrations of 
the instrument. This report has obvious clinical utility, because a clinician can track a 
patient’s distress scores over time.
Similar to the HADS, a limitation of the BSI-18 is the cost of obtaining the instrument and 
scoring the instrument (depending on the options chosen) for routine screening of all cancer 
patients. Furthermore, scoring can be complicated and, if done as the publisher suggests, 
cannot be used immediately in the clinical setting (e.g., to refer a patient to an OSW) 
without use of the PAD and its scoring/printing docking station. The complexity of the 
scoring algorithm is due to the ability to compare BSI-18 scores to established norms. It 
should be noted that this comparison ability is a strength of the BSI-18 in research 
applications but adds to the complexity of clinical applications. Consequently, the additive 
scoring mechanism noted previously (Zabora et al., 2001) can serve clinical settings more 
easily and efficiently.
Distress Thermometer
The Distress Thermometer (DT), developed by the NCCN, is an ultrashort, single-item self-
report instrument that measures a patient’s level of distress over the past week on an 11-
point, visual analog scale (resembling a thermometer) that ranges from 0 (no distress) to 10 
(extreme distress). A cutoff score of 4 is associated with an optimal balance of sensitivity 
and specificity and indicates need for further psychosocial assessment and referral or 
intervention (Jacobsen et al., 2005; Ransom, Jacobsen, & Booth-Jones, 2006). The DT is 
sometimes accompanied by a Problem List for patients to specify the source of their distress: 
practical problems, emotional concerns, family problems, nutrition problems, and spiritual/
religious concerns.
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Strengths and limitations—The brevity of the DT enhances its ease of use and limits 
the resources needed to score and interpret the results. DT results are immediately available 
for clinical use. Studies have shown that the DT can discriminate between cancer patients 
with and without clinically significant distress comparably to the HADS and the BSI-18 
(Hoffman et al., 2004; Jacobsen et al., 2005). Another benefit of the DT is that it is available 
at no cost, after obtaining permission from the NCCN (2012). Finally, the DT has been 
successfully adapted for use across multiple languages and cultures (Absolom et al., 2011; 
Akizuki et al., 2003; Dolbeault, Boistard, Meuric, Copel, & Brédart, 2011; Grassi et al., 
2011; Ito et al., 2011; Vodermaier et al., 2009) and is suitable to administer to low-literacy, 
often more vulnerable, patients.
There is evidence to suggest that the DT has only moderate specificity (ranging from .49 to .
82) and thereby misses identifying some distressed patients (Vodermaier et al., 2009). 
However, in a recent meta-analysis of distress screening tools, Mitchell (2010) found that 
combining the use of the DT with the Impact Thermometer (IT) raised the sensitivity and 
specificity of the combined measure to .81 and .82, respectively. Furthermore, the use of the 
Problem List has been shown to increase the utility of the DT (Jacobsen et al., 2005; 
Kendall, Glaze, Oakland, Hansen, & Parry, 2011; Mitchell, 2010; Mitchell, Vahabzadeh, & 
Magruder, 2011) and can be used to help identify which provider can best address a 
patient’s concerns, thereby facilitating referral to the appropriate type of professional (OSW 
or other psychosocial provider, dietician, chaplain, etc.).
CONSIDERATIONS FOR OSWS
Armed with the knowledge of the psychometric properties and feasibility of the HADS, 
BSI-18, and the DT, other issues that are important in the implementation of distress 
screening for cancer patients must be considered. First, it is essential to consider screening 
equally across cultures and populations. Who are we screening with these methods? Who 
are we missing? What do we need to do to ensure we are screening all populations we serve 
equally? The evidence suggests current distress screening may be missing the most 
vulnerable persons (Carlson & Bultz, 2003; Kayser, Acquati, & Tran, 2012). One notable 
point to mention is that racial disparities exist. Despite studies that have shown increased 
levels of distress in non-White cancer patients (Carlson & Bultz, 2003; Hoffman et al., 
2004), racial disparities in screening for and treating distress still exist. For example, one 
study found Whites to be nearly 7 times more likely to be assessed for depression than non-
Whites (Tai-Seale et al., 2005), and another found Whites to be more likely to be treated for 
depression than non-Whites (Tai-Seale, McGuire, Colenda, Rosen, & Cook, 2007). 
Furthermore, Whites are over-represented in many of the studies of the efficacy of distress 
screening in cancer patients (Carlson & Bultz, 2003; Hoffman et al., 2004; Kayser et al., 
2012). The cultural aspects of distress screening are addressed in depth elsewhere in this 
special issue (Kayser et al., 2012).
Another point to consider is related to cutoff scores of screening instruments. As noted for 
each of the three instruments, cutoff scores have been established in the literature to 
maximize the sensitivity (true-positives) and specificity (true-negatives) for each measure. 
Adhering to published cutoff scores is important, because false-positives will generate 
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referrals to OSWs unnecessarily, whereas false-negatives will leave distressed patients 
without psychosocial intervention. Yet using an established cutoff score can generate more 
psychosocial referrals than current psychosocial staffing levels can respond to. How will 
your setting handle this dilemma? Is it ethical to screen for distress using published cutoff 
scores, but then not have sufficient staff to respond? On the other hand, is it ethical and wise 
to raise cutoff scores arbitrarily to make sure that only the most distressed patients reach the 
threshold to receive psychosocial services?
In clinical terms, the principal consideration is as follows: If we screen someone, are there 
the resources to help? Screening for distress is a necessary, but not sufficient, aspect of the 
endeavor to care for the psychosocial needs of oncology patients. The challenge is not only 
to incorporate routine distress screening into cancer care but also to meet the needs of 
patients who are distressed (CoC, 2012). Additionally, routine screening has been shown to 
shift psychosocial caseloads to a more diverse patient population with complex needs 
(Zabora et al., 2003). Meeting this increased need may necessitate expansion of social work 
roles and availability of services in some oncology health care settings. As Zabora and 
others (Cunningham, 1995; Zabora & Knight, 2001) have noted, psychosocial support can 
be provided in myriad ways, depending on the level of intervention needed by a particular 
patient. The least distressed patients may get their needs met through psychoeducational 
seminars or patient-to-patient support. More distressed patients may require crisis 
intervention, support groups, and/or short-term therapy. The most distressed patients 
generally require psychotherapy and family therapy (Zabora & Knight, 2001). OSWs, with 
their professional training, along with the profession’s longstanding experience in providing 
psychosocial care to cancer patients and their significant others, are well poised to respond 
and match services to service needs along this continuum.
If there are not enough OSWs to appropriately address the distress of patients in oncology 
settings, it will be more costly for the health care system in the long run. It is well 
documented that distressed patients incur more unnecessary medical costs than do patients 
who are not distressed because the former have “more difficulty making decisions, are more 
likely to miss appointments, are less adherent to their treatment regimens, and are less 
satisfied with their medical care” (Hoffman et al., 2004, p. 792; see also Bottomley & 
Hunton, 1996; Carlson & Bultz, 2003; and Holland, 1999). Routine distress screening of 
oncology patients, when accompanied by appropriate psychosocial treatment, is likely to not 
only improve the overall care of cancer patients but also maximize health care resources.
Finally, the context of the oncology delivery setting must be carefully considered prior to 
implementing a routine screening program. Although the CoC (2012) now requires 
screening for psychosocial distress for every cancer patient treated in ACoS-accredited 
facilities, it has not given specific guidance on how to do this. Facilities must decide for 
themselves which screening tool to use, at what intervals along the illness trajectory to 
screen patients, and what do to with the results of such screening. Studies have shown that 
the best way to enhance routine screening in oncology settings it to use an instrument that is 
acceptable not only to patients but also to providers (Absolom et al., 2011; Mitchell, 2010; 
Mitchell et al., 2008).
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The current climate in health care recognizes what OSWs have historically known: that 
quality cancer care requires identifying and addressing the psychosocial needs of cancer 
patients (IOM, 2008). Planning for the implementation of screening entails knowing the 
efficacy of the distress screening instruments used in oncology settings, articulating a given 
instrument’s strengths and weakness, assessing the needs and interests of staff at one’s 
institution, knowing the context and needs of the facility’s patient population, and, finally, 
arriving at consensus regarding how to best implement routine screening. OSWs have an 
excellent vantage point from which to play a leadership role in planning how to implement 
routine distress screening in their oncology care delivery settings.
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